Hepatic MRI with SPIO: Detection and characterization of focal liver lesions

European Radiology

Volumn 8, Issue 7, 1998, Pages 1198-1204

  Reimer, P ^a   Tombach, B ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Iron oxides; Liver; SPIO; USPIO

Indexed keywords

CONTRAST MEDIUM; DIAGNOSTIC AGENT; IRON; OXIDE; SUPERPARAMAGNETIC IRON OXIDE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

HUMAN; LIVER; LIVER DISEASE; LIVER TUMOR; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; REVIEW; SUSPENSION;

CONTRAST MEDIA; HUMANS; IRON; LIVER; LIVER DISEASES; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; OXIDES; SUSPENSIONS;

EID: 0031616365     PISSN: 09387994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003300050535     Document Type: Review

References (38)

1. Low RN (1997) Contrast agents for MR imaging of the liver. J Magn Reson Imaging 7: 56
2. Weissleder R (1994) Liver MR imaging with iron oxides: toward consenus and clinical practice. Radiology 193: 593
3. Hamm B, Staks T, Taupitz M, et al (1994) Contrast enhanced MR imaging of liver and spleen: first experience in humans with a new superparamagnetic iron oxide. J Magn Reson Imaging 4: 659
4. Josephson L, Lewis J, Jacobs P, Hahn PF, Stark DD (1988) The effects of iron oxides on proton relaxivity. Magn Reson Imaging 6: 647
5. McLachlan SJ, Morris MR, Lucas MA, et al (1994) Phase I clinical evaluation of a new iron oxide MR contrast agent. J Magn Reson Imaging 4: 301
6. Weissleder R, Stark DD, Engelstad BL, et al (1989) Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR 152: 167
7. Hahn PF, Stark DD, Elizondo G, Weissleder R, Saini S, Ferrucci JT (1990) Clinical application of superparamagnetic iron oxide to MR imaging of tissue perfusion in vascular liver tumors. Radiology 174: 361
8. Yamamoto H, Yamashita Y, Yoshimatsu S, et al (1995) Hepatocellular carcinoma in cirrhotic livers: detection with unenhanced and iron oxide-enhanced MR imaging. Radiology 195: 106
9. Bellin MF, Zaim S, Auberton E, et al (1994) Liver metastases: safety and efficacy of detection with superparamagnetic iron oxide in MR imaging. Radiology 193: 657
10. Ros PR, Freeny PC, Harms SE, et al (1995) Hepatic MR imaging with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions. Radiology 196: 481
11. Vogl TJ, Hammerstingl R, Schwarz W, et al (1996) Superparamagnetic iron oxide-enhanced versus gadolinium-enhanced MR imaging for differential diagnosis of focal liver lesions. Radiology 198: 881
12. Reimer P, Rummeny EJ, Daldrup HE, et al (1995) Clinical results with Resovist: a phase 2 clinical trial. Radiology 195: 489
13. Stark DD, Weissleder R, Elizondo G, et al (1988) Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver. Radiology 168: 297
14. Winter TC III, Freeny PC, Nghiem HV, et al (1993) MR imaging with IV superparamagnetic iron oxide: efficacy in the detection of focal hepatic lesions. AJR 161: 1191
15. Duda SH, Laniado M, Kopp AF, et al (1994) Superparamagnetic iron oxide: detection of focal liver lesions at high-field-strength MR imaging. J Magn Reson Imaging 4: 309
16. Hamm B, Reichel M, Vogl T, Taupitz M, Wolf K-J (1994) Superparamagnetische Eisenpartikel: klinische Ergebnisse in der MR-Diagnostik von Lebermetastasen. ROFO 160: 52
17. Reimer P, Marx C, Rummeny EJ, et al (1997) SPIO-enhanced 2D-TOF MR-angiography of the portal venous system: results of an intraindividual comparison. J Magn Reson Imaging 7: 945-949
18. Weissleder R, Elizondo G, Wittenberg J, Rabito C, Bengele HH, Josephson L (1990) Ultrasmall superparamagnetic iron oxide (USPIO): characterization of a new class of MR contrast agents. Radiology 175: 489
19. Bengele HH, Palmacci S, Rogers J, Jung CW, Crenshaw J, Josephson L (1994) The biodistribution of an ultrasmall superparamagnetic iron oxide colloid, BMS 180549, by different routes of administration. Magn Reson Imaging 12: 433-442
20. Deckers F, Corthouts B, Nackaerts Y, Ozlarlak O, Parizel PM, De Schepper AM (1997) The influence of MR field strength on the detection of focal liver lesions with superparamagnetic iron oxide. Eur Radiol 7: 887
21. Marchal GY, van Hecke P, Demaerel P, et al (1989) Detection of liver metastases with superparamagnetic iron oxides in 15 patients: results of MR imaging at 1.5 T. AJR 152: 771
22. Seneterre E, Taourel P, Bouvier Y, et al (1996) Detection of hepatic metastases: ferumoxides-enhanced MR imaging versus unenhanced MR imaging and CT during arterial portography. Radiology 200: 785
23. van Gansbeke D, Metens TM, Matos C, et al (1997) Effects of AMI-25 on liver vessels and tumors on T1-weighted turbo-field-echo images: implications for tumor characterization. J Magn Reson Imaging 7: 482
24. Oudkerk M, van den Heuvel AG, Wielopolski PA, Schmitz PIM, Borel Rinkes IHM, Wiggers T (1997) Hepatic lesions: detection with ferumoxide-enhanced T1-weighted MR imaging. Radiology 203: 449
25. Saini S, Edelman R, Sharma P, et al (1995) Blood-pool MR contrast material for detection and characterization of focal hepatic lesions: initial clinical experience with ultrasmall superparamagnetic iron oxide (AMI-227). AJR 164: 1147
26. Reimer P, Rummeny EJ, Marx C, et al (1997) Characterization of focal liver lesions by means of enhancement on T2-w FSE MRI with the new SPIO Resovist: results of a phase III study. ECR'97, European Congress of Radiology, Vienna, p 171
27. Grandin C, van Beers BE, Robert A, Gigot JF, Geubel A, Pringot J (1995) Benign hepatocellular tumors: MRI after superparamagnetic iron oxide administration. J Comput Assist Tomogr 19: 412
28. Reimer P, Rummeny EJ, Marx C, et al (1997) Characterization of focal liver lesions with Resovist as a new SPIO: clinical value of dynamic enhancement with T1- and T2-weighted MRI. ECR'97, European Congress of Radiology, Vienna, p 293
29. Harisinghani MG, Saini S, Weissleder R, et al (1997) Differentiation of liver hemangiomas from metastases and hepatocellular carcinoma at MR imaging enhanced with blood-pool contrast agent code-7227. Radiology 202: 687
30. Vogl TJ, Hammerstingl R, Schwarz W, et al (1996) Magnetic resonance imaging of focal liver lesions: comparison of the superparamagnetic iron oxide Resovist versus gadolinium-DTPA in the same patient. Invest Radiol 31: 696
31. Yamamoto H, Yamashita Y, Yoshimatsu S, Baba Y, Takahashi M (1995) MR enhancement of hepatoma by superparamagnetic iron oxide (SPIO) particles. J Comput Assist Tomogr 19: 665
32. Reimer P, Rummeny EJ, Marx C, et al (1997) Clinical evaluation of a new SPIO (Resovist) for the complete work-up of focal liver lesions. Fifth Scientific Meeting of the international Society for Magnetic Resonance in Medicine, Vancouver, p 70
33. Mergo PJ, Helmberger T, Nicolas AI, Ros PR (1996) Ring enhancement in ultrasmall superparamagnetic iron oxide imaging: a potential new sign for characterization of liver lesions. AJR 166: 379
34. Mayo-Smith WW, Saini S, Slater G, Kaufman JA, Sharma P, Hahn PF (1996) MR contrast material for vascular enhancement: value of superparamagnetic iron oxide. AJR 166: 73
35. Anzai Y, Prince MR, Chevenert TL, et al (1997) MR angiography with an ultrasmall superparamagnetic iron oxide blood pool agent. J Magn Reson Imaging 7: 209
36. Prince M, Yucel EK, Kaufman JA, Harrison DC, Geller SC (1993) Dynamic gadolinium-enhanced 3DFT abdominal MR arteriography. J Magn Reson Imaging 3: 877
37. Knollmann FD, Böck JC, Teltenkötter S, et al (1997) Evaluation or portal MR angiography using superparamagnetic iron oxide. J Magn Reson Imaging 7: 191
38. Frank H, Weissleder R, Brady TJ (1994) Enhancement of MR angiography with iron oxide: preliminary studies in whole-blood phantom and in animals. AJR 162: 209